Strategies for Prevention of Neural Tube Defects by Hiroko Watanabe & Tomoyuki Takano
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
2 
Strategies for Prevention  
of Neural Tube Defects 
Hiroko Watanabe1 and Tomoyuki Takano2 
1Department of Clinical Nursing, 
2Department of Pediatrics, Shiga University of Medical Science  
Japan 
1. Introduction 
Neural tube defects (NTDs) are congenital malformations of the brain and spinal cord 
caused by the failure of neural tubes to close between 21 and 28 days after conception 
(Sadler, 2005). Any disruption of neurulation during or prior to this time may result in a 
defect or failure of neural tube closure. Non-invasive prenatal diagnostic testing by 
ultrasound and maternal serum screening, which should be offered at 16 to 20 weeks 
gestation and 15 to 20 weeks gestation, respectively, will identify 95% of spina bifida and 
100% of anencephaly cases. After 15 weeks of pregnancy, invasive prenatal diagnostic 
testing with ultrasound-guided amniocentesis can evaluate the fetal karyotype and measure 
amniotic fluid alpha-fetoprotein and acetylcholinesterase, to assist in differentiating 
between open or closed lesions (Chodirker et.al., 2001). The majority of cases can be 
categorized as either anencephaly (lack of closure in the region of the head) or spina bifida 
(lack of closure below the head). 
Folate deficiency before conception and during early pregnancy is one potential cause of 
NTDs. Folate is the general term for water soluble B vitamin predominantly found in green 
leafy vegetables. Adequate folate intake is required for normal metabolism, cell division, 
neural function and growth. Humans are unable to synthesize folate and depend on an 
adequate and constant intake. Both observational and interventional studies, including 
randomized, controlled trials, have demonstrated that adequate consumption of folic acid 
periconceptionally can prevent 50-70% of NTDs (Czeizel & Dudas, 1992).  
Currently, 57 countries have regulations for mandatory fortification of wheat flour with folic 
acid, (Flour Fortification Initiative, 2009) and health agencies in many countries have 
officially recommended the periconceptional consumption of folic acid in the range of 400 to 
500 μg in young women of reproductive age who are capable of conceiving or planning to 
conceive (Centers for Disease Control and Prevention [CDC], 1992; Bower et al., 1995). The 
prevalence of spina bifida and anencephaly in the United States has declined significantly 
since the onset of fortification of enriched grain products with folic acid. The latest 
prevalence of spina bifida and anencephaly rates in the United States, reported in 2006, was 
3.05 and 1.56 per 10,000 live births, respectively (Neural tube defect ascertainment project, 
2010). On the other hand, the incidence of spina bifida in countries in which the fortification 
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of enriched grain product with folate is not compulsory or endorsed officially, was 5.32 per 
10,000 live births (Annual report 2007 with data 2005, 2009). The primary objective of this 
review article is to discuss the strategies for prevention of NTDs. 
2. Definition and classification 
NTDs are common and severe congenital malformations of the central nervous system 
occurring secondary to a lack of closure of the neural tube. The following three groups are 
categorized based on the severity of the defects (Copp & Harding, 2004).  
2.1 Severe form 
The severe form of the NTD spectrum includes open defects resulting from the failure of 
neural tube closure, in which the interior of the brain or spinal cord communicates directly 
with outside, and includes the following: 
 Craniorachischisis: There is an almost complete absence of neural tube closure, affecting 
both the brain and spine. This malformation results from a failure of the initiating event 
of neurulation in the early embryo.  
 Excencephaly: This is a brain defect resulting from a failure of cranial neural tube 
closure. Although this appearance is seen only in embryos and early fetuses, the 
persistently open cranial neural folds have an everted appearance.  
 Anencephaly: Exposed cranial neural folds may degenerate with advancing gestation. 
This is a catastrophic malformation in which the brain is severely degeneratd and the 
skull vault is absent.  
 Myelomeningocele: This results from a failure of the closure of the spinal neural tube, 
most often in the lumbosacral region. In spina bifida cystica, a meningeal sac containing 
the open spinal cord herniates through a vertebral defect. In myeloceles, the open spinal 
cord is directly exposed as a flat open lesion.  
2.2 Moderate form 
The moderate form of NTD includes encephaloceles and meningoceles. These defects result 
from herniation of the brain or meninges through an opening in the skull or vertebral 
column, respectively. These defects appear to be primary abnormalities of skeletal 
development, not neural tube closure, as the brain and spinal cord appear to have closed 
normally prior to herniation. 
2.3 Mild form 
The mild end of the NTD spectrum is represented by a third group of dysraphic defects in 
which there are closed abnormalities of the spinal cord, usually in the low lumbar and sacral 
regions. The following types are included:  
 Diplomyelia: This is a side-by-side or anteroposterior duplication of the spinal cord. 
 Diastematomyelia: A midline septum divides the spinal cord longitudinally into two 
usually unequal portions extending up to 10 thoracolumbar segments. 
 Hydromyelia: The central canal is overdistended (Fig. 1). 
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 Lipomeningocele: The dysraphic spinal cord is accompanied by fatty tissue deposits. 
 Spina bifida occulta: This is defined as a defect in the posterior bony components of the 
vertebral column without involvement of the cord or meninges. 
 
Source; Modified from Takano, T. & Becker, L.E. (1997).  
Fig. 1. A coronal section of the spinal cord in a patient with a meningomyelocele. Note the 
overdistended and deformed central canal showing hydromyelia. Hematoxylin and eosin 
staining. 
3. Clinical features and management 
3.1 Craniorachischisis, excencephaly and anencephaly 
These malformations are incompatible with survival beyond birth and today are observed 
almost exclusively on ultrasound examination during pregnancy.  
3.2 Myelomeningocele 
Myelomeningoceles involve all of the underlying layers, including the spinal cord, nerve 
roots, meninges, vertebral bodies and skin. The spinal cord may be exposed because of a 
complete failure of neural closure, or may be covered by a membrane. Although 
myelomeningocele may be situated at any longitudinal level of the neuroaxis, lumbosacral 
involvement is the most common (Fig. 2). Varying degrees of paresis of the legs, usually 
profound, and sphincter dysfunction are the major clinical manifestations. Fifty to seventy 
percent of neural tube defects can be prevented if a woman consumes sufficient folic acid 
daily before conception and throughout the first trimester of her pregnancy (Gleeson et al., 
2006). Maternal serum alpha-fetoprotein determination and ultrasound examination are 
now routinely used to identify fetuses that have or are likely to have spina bifida or 
anencephaly (Drugan et al., 2001). Alpha-fetoprotein is a component of the fetal 
cerebrospinal fluid, and it may leak into the amniotic fluid from the open neural tube. 
Closed lesions often do not lead to increased alpha-fetoprotein concentrations. The 
management of a child with a myelomeningocele requires the concerted efforts of a 
multidisciplinary team involving many specialists. Treatment includes surgical reduction of 
the myelomeningocele and other associated defects, prevention of infection, covering of the 
myelomeningocele, control of hydrocephalus, management of urinary dysfunction, and 
treatment of the paralysis and abnormalities of the hips and feet (Gleeson et al., 2006). 
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Fig. 2. A lumbar myelomeningocele in a newborn, showing a large meningeal sac (asterisk). 
The midline sagittal view from a computed tomography study. 
3.3 Meningocele 
A meningocele is a protrusion of the meninges without accompanying nervous tissue, and it 
is not associated with neurological deficits. The mass usually is evident as a fluid-filled 
protrusion covered by skin or a membrane in the midline. When careful examination of 
patients with a suspected meningocele reveals significant neurological abnormalities such as 
the equinovarus deformity, gait disturbance or abnormal bladder function, the diagnosis of 
a meningomyelocele is appropriate. A meningocele can be found in the cranial (Fig. 3) or 
high cervical area.  
 
Fig. 3. A cranial meningocele in a newborn. Note the meningeal herniation through a small 
opening of the frontal skull (arrow) into the nasal cavity. The midline sagittal view from a 
magnetic resonance imaging study.  
3.4 Encephalocele 
An encephalocele is a herniation of the intracranial contents through a midline skull defect. 
The cranial meningoceles contain only leptomeninges and cerebrospinal fluid, whereas 
encephaloceles also contain brain parenchyma. The amount of compromised and deformed 
neural tissue and the degree of resultant microcephaly determine the extent of cerebral 
dysfunction (Gleeson et al., 2006). Severe intellectual and motor delays typically occur in 
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association with microcephaly. A prenatal diagnosis of encephaloceles may be established by 
the determination of an increased amniotic alpha-fetoprotein content and ultrasound studies 
(Graham et al., 1982). Surgical corrections of all but the smallest encephaloceles are necessary.  
3.5 Diplomyelia 
This malformation is compatible with normal spinal function, and neurological 
deterioration suggests the presence of diastematomyelia or tethering. 
3.6 Diastematomyelia 
Patients with diastematomyelia present with congenital scoliosis, hydrocephalus, or 
cutaneous lesions such as hairy patch, dimple, hemangioma, subcutaneous mass, or 
teratoma (Kothari & Bauer, 1997). A progressive myelopathy, with deformities of the feet, 
scoliosis, kyphosis, or discrepancy in leg length, also may develop. Resection of the spur in 
diastematomyelia frequently does not result in any clinical improvement. 
3.7 Spina bifida occulta 
This occurs in at least 5% of the population, but most often is asymptomatic. This defect is 
often found incidentally on radiographic studies or is diagnosed because of a subtle clinical 
finding, such as a tuft of hair or a cutaneous angioma or lipoma in the midline of the back 
marking the location of the defect (Guggisberg et al., 2004).  
4. The mechanism of folate deficiency and NTDs 
In 1976, Smithells et al. (1976) suggested that folate deficiency was a cause of NTDs because 
women with NTDs infants had low blood folate levels. Later, they reported that 
periconceptional vitamin supplementation, including folic acid, reduced the recurrence of 
NTDs (Smithells et al., 1983). Further studies provided a growing body of evidence. Folic 
acid exists as polyglutamates in green leafy vegetables and other natural sources. It consists 
of a pteridine ring, p-aminobenzoic acid, and glutamine acid. Although folate deficiency is 
an established risk factor for NTDs, the exact mechanism is not clear.  
Beaudin and Storver (2007) showed the pathway linking alterations in folate status with 
NTDs (Fig. 4). They summarized that disruption of folate metabolism could result in 
homocysteine accumulation, impaired nucleotide biosynthesis, and impaired cellular 
methylation. These metabolic impairments evoke genomic responses such as alterations in 
gene expression, genomic instability, reduced mitotic rates, and impaired DNA repair. 
Impairments in metabolism and/or genomic responses may influence cellular responses 
critical to proper neural tube closure, including cell proliferation, survival, differentiation, and 
migration. SNPs in folate-related genes can influence both maternal and infant folate status, or 
alternatively, Aminopterin (4-aminopteroic acid; APN) can also directly disrupt metabolism. 
APN is an antineoplastic drug with immunosuppressive properties used in chemotherapy and 
a synthetic derivative of pterin, and works as an enzyme inhibitor by competing for the folate 
binding site of the enzyme dihydrofolate reductase. Its binding affinity for dihydrofolate 
reductase effectively blocks tetrahydrofolate synthesis. This results in the depletion of 
nucleotide precursors and inhibition of DNA, RNA, and protein synthesis. 
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Source: Beaudin, A.E. & Stover, P.J. (2007) 
Fig. 4. Pathway linking alterations in folate status with NTDs  
5. Strategies for prevention of NTDs 
The prevalence of NTDs has declined considerably during the past three decades, due to 
advances in the refined resolution of ultrasonography for fetal examination, the clinical 
availability of serum alpha-fetoprotein measurements, termination of affected pregnancies, 
and the consumption of folic acid supplements among reproductive-aged women. Included 
in these factors, successful mandatory fortification programs have been documented in 
several countries, including the United States, Canada, and Australia (Abeywardana et al., 
2010; De Wals et al., 2008; Pfeiffer et al., 2008). 
5.1 Countries of fortification of enriched grain product with folate 
5.1.1 Mandated folic acid fortification programs 
In 1992, the U.S. Public Health Service recommended that all women of reproductive age in 
the United States who were capable of becoming pregnant should consume 400 μg of synthetic 
folic acid daily from fortified foods and/or supplements and that they should consume a 
balanced, healthy diet of folate-rich food in order to reduce the risk of NTDs (CDC, 1992). The 
Food and Drug Administration mandated the addition of folic acid to all enriched cereal grain 
products by January 1998 (Food and Drug Administration, 1996). In 2009, the U.S. Preventive 
Services Task Force (2009) published updated guidelines reinforcing these recommendations.  
Canada introduced a fortification program in 1998, mandating the folic acid fortification of 
enriched white flour, as well as some corn and rice products, with ranges from 95 to 309 
μg/100 g for different products (Ray et al., 2002). In Australia, the Australian National 
Health and Medical Research Council recommended a periconceptional daily supplement 
intake of 500 μg folic acid for women of childbearing age in 1993, and voluntary folic acid 
fortification of certain foods was permitted (National Health and Medical Research Council, 
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1994). In June 2007, the Australian Food Regulatory Ministerial Council agreed to 
mandatory fortification of bread-making flour with folic acid. The standard, September 
2009, requires the mandatory addition of 200-300 μg folic acid per 100 grams of bread-
making flour (Food Liaison, 2007).  
The percentage of the world’s wheat flour produced in large roller mills that is fortified has 
increased from 18% to 30%. By 2015, the target date of the World Health Organization 
millennium Development Goals, the Flour Fortification Initiative goal is for 80% of the 
world’s roller-mill wheat flour to be fortified (CDC, 2010). 
5.1.2 The effect of fortification 
According to the Morbidity and Mortality Weekly Report, if 50%-70% of NTDs can be 
prevented through daily consumption of 400 μg of folic acid, assuming an annual 
prevalence of 300,000 NTDs, worldwide folic acid fortification could lead to the prevention 
of 150,000 - 210,000 NTDs per year (CDC, 2010).  
Numerous studies have evaluated the effect of folic acid fortification on primary prevention 
of NTDs. A significant, worldwide decline in the prevalence of NTDs was noted in the 
period following folic acid fortification. In the United States, during 1995-1996, an NTD 
affected approximately 4,000 pregnancies. The number declined to 3,000 pregnancies in 
1999-2000, following the mandated fortification of enriched cereal grain products with folic 
acid (CDC, 2004). From the prefortification period of 1996-1996 to the early postfortification 
of 1999-2000, the prevalence of spina bifida and anencephaly decreased dramatically (CDC, 
2008). The latest prevalence of spina bifida and anencephaly rates in the United States, 
reported in 2006, was 3.05 and 1.56 per 10,000 live births, respectively, based on birth defects 
surveillance data (Neural tube defect ascertainment project, 2010) (Fig. 5).  
 
Source by neural tube defect ascertainment project of the National Birth Defects Prevention Network at 
Centers for Disease Control and Prevention. 
*NTDs: Spina bifida + Anencephaly  
Fig. 5. Prevalence of spina bifida and anencephaly in the United States, 1995-2006 
Australia presented similar findings. The prevalence of NTDs dramatically declined from 20 
per 10,000 births in the prefortification period to 5 per 10,000 births in the postfortification 
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period. A declining trend of 26% was seen during this period (Abeywardana et al., 2010). Chan 
et al. (2008) reported a decline in the total prevalence of NTDs from 2.06 per 1,000 births in the 
prefortification period to 1.23 per 1,000 births in the mandatory fortification period (RR: 0.60, 
95% confidence interval (CI): 0.48-0.74; p<0.001). Sayed et al. (2008) showed that the prevalence 
of spina bifida decreased from 1.41 per 1,000 births in the prefortification period to 0.98 per 
1,000 births in the mandatory fortification period (RR: 0.69, 95% CI: 0.49-0.98). Ten studies 
suggested that food fortification could reduce the incidence of NTDs by 20 to 50%.  
The effect of folic acid fortification on the incidence of NTDs has also reported in Jordan. 
Seventy-eight NTDs were recorded among 61,447 births between 2000 and 2006 at a Jordan 
hospital. Of the cases, spina bifida was the most common type of anomaly (87.2%), followed 
by encephalocele (11.5%), and anencephaly (1.3%). The incidence of NTDs decreased from 
1.85 (95% CI; 1.2-2.4)per 1000 births before fortification (2000-2001) to 1.07 (95% CI; 0.7-1.5) 
during the fortification period (2002-2004), and to 0.95 (95% CI; 0.5-1.5) after full fortification 
(2005-2006), a 49% reduction (Amarin & Obeidat, 2011). Thus, the folic acid fortification 
strategy was clearly successful in some countries.  
5.1.3 Blood folate levels after fortification 
The mandatory fortification of standardized enriched cereal grain products in the United 
States has resulted in a substantial increase in blood folate concentrations. The percentage of 
the population with low serum folate (<3 ng/mL) declined from 21% in the period before 
fortification (1988-1994) to <1% of the total population in the period immediately following 
fortification (1999-2000) (Pfeiffer et al., 2008). In a study based on data from the National 
Health and Nutrition Examination Survey (NHANES), the mean serum folate concentration 
for women aged 15-44 years who did not use supplements increased from 10.7 nmol/L to 28.6 
nmol/L shortly after the initiation of fortification in the United States, representing an almost 
threefold increase (CDC, 2000). In the most recent analysis of NHANES data, the CDC 
reported a 16% decline in serum folate concentrations among women aged 15-44 years from 
1999-2000 to 2003-2004; red blood cell folate concentrations decreased 8% over the same time 
periods (CDC, 2007). The reason of these different decreased rate may that red blood cell folate 
concentrations reflect body stores at the time of red cell synthesis and are considered a better 
measure of long-term folate status (>3 months) than serum folate concentrations, which reflect 
recent dietary intake (Scientific Advisory Committee on Nutrition, 2006).  
In Australia, researchers examined the impact of mandatory fortification of flour with folic 
acid on the blood folate levels in 20,592 Australians, including in women of childbearing age 
between 2009 and 2010. In 2010, there was a 31% increase in mean serum folate levels (from 
17.7 nmol/L to 23.1 nmol/L), and a 22% increase in mean red blood cell (RBC) folate levels 
(from 881 nmol/L to 1071 nmol/L) after mandatory fortification with folic acid of wheat 
flour used in bread making among women of childbearing age (Brown et al., 2011). The 
introduction of mandatory fortification with folic acid has significantly reduced the 
prevalence of folate deficiency.  
5.2 Countries with voluntary fortification of enriched grain products with folate 
Countries where the fortification of enriched grain products with folate is not compulsory or 
officially endorsed report low folate status among reproductive-aged women and high 
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incidences of NTDs. Japan is one such country, although 440 μg of dietary folate with 
balanced meals was recommended to all Japanese women of reproductive age by the 
Ministry of Health (2000) to prevent birth defects. In 2008, the National Nutrition Survey in 
Japan reported that the mean dietary intake of folate, vitamin B6, and vitamin B12 of non-
pregnant women aged 18-29 years was less than the recommended dietary allowance (RDA) 
(Ministry of Health, Labour and Welfare, 2008). Another study showed (Mito et al., 2007) 
that more than 80% of Japanese women aged between 17 and 41 had inadequate (i.e., less 
than the RDA of 240 μg/d) folate intake in 2002. This failure of women to meet the RDA for 
folate intake may have lead to the increase in the prevalence of spina bifida from1.96 per 
10,000 live births (1974-1980) to 5.32 (2001-2005) (Annual report 2007 with data 2005, 2009).  
In China, women who are planning marriage or pregnancy are advised to take 400 μg of 
supplemental folic acid every day, starting before conception, through to the end of the first 
trimester of pregnancy, but this is not mandatory (Ren et al., 2006). Northern China has one of 
the highest reported NTD birth prevalence rates in the world. The prevalence of NTDs was 4.5 
per 1,000 in 2002 (Zhang & Wang, 2004), and only 35.8% of the affected population was aware 
of folic acid; fewer than 15% of women reported taking folic acid periconceptionally, with the 
percentage being significantly lower than the average among rural farming women with less 
education (Ren et al., 2006). The low level of awareness as well as the low reported rate of 
periconceptional supplementation may explain the high prevalence of NTDs. 
6. Feature approaches  
There have been three main approaches to reduce the incidence of NTDs: health promotion 
to improve the knowledge and awareness of folic acid, ensuring the use of fortified folic acid 
and folic acid supplements, and reducing the number of obese women, which is also a 
known environmental factor (Waller et al., 1994; Werler et al., 1996).  
6.1 Health promotion to improve knowledge and awareness regarding folic acid 
The USA, Canada, and Australia have implemented food fortification programs successfully 
with resultant improvement in serum folate levels and reduction in incidences of NTDs. 
Education campaigns can be effective and public health campaigns aimed at informing and 
influencing behavioral change in all individuals. Rofail et al. (2011) examined pre- and post-
campaign awareness, knowledge, and consumption data for women of reproductive-age in 
Australia. Awareness of folic acid improved post-campaign, with the percentage improvement 
between pre- and post-campaigns ranging from 6 to 41%. Women’s knowledge of the 
association between folate and spina bifida increased from 8% before the program began to 
67% two-and-a-half years later. The proportion of women taking periconceptional folic acid 
supplements increased from 13% to 30% over the same period (Bower et al., 1997). Since the 
introduction of this promotion, the prevalence of NTDs in Western Australia, which was about 
two per 1,000 births from 1980 until 1995, fell by 30% in 1996 (Bower et al., 2002). The 
estimated increase in mean serum folate concentration was 19% after educational campaigns 
to increase periconceptional folic acid use (Metz et al., 2002). The ultimate goal of any folic acid 
awareness campaign is to promote use of folic acid supplements, to increase the blood folate 
levels of women, and to prevent the occurrence of NTDs.  
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An U. S. national survey showed differences in folic acid awareness and knowledge among 
age groups (CDC, 2008). In 2007, approximately 61% of women aged 18-24 years reported 
being aware of folic acid, compared to 87% of women aged 25-34 years and 89% of women 
aged 35-45 years. Women aged 18-24 years were also less knowledgeable about the need for 
folic acid consumption before pregnancy (6%), compared to women aged 35-45 years (16%). 
In addition, approximately 33% of women who were aware of folic acid had received the 
information about folic acid from their health-care providers, followed by finding 
information in a magazine or newspaper (31%) and receiving it through radio or television 
(23%). Official health education initiatives have promoted folic acid supplementation and a 
diet rich in folates through mass media, including TV, newspapers, and magazine articles 
worldwide (CDC, 2010). Special attention and targeted approaches must concentrate on this 
age group. Public health campaigns aimed at increasing awareness, knowledge, and 
periconceptional use of folic acid should concentrate on using appropriate intervention 
methods worldwide. 
6.2 Encouragement to increase women’s dietary intake of folic acid and use of folic 
acid supplements 
Many women of childbearing age in the United States do not maintain a healthy diet prior 
to, during, or after pregnancy. Numerous studies have reported that women in the United 
States do not consume the recommended 400 μg of folic acid (Hilton, 2007; Rinsky-Eng & 
Miller, 2002). In Japan, more than 80% of Japanese women between 17 and 41 years of age 
had inadequate folate intake - less than the recommended daily allowance of 240 μg/d 
(Mito et al., 2007; Watanabe et al., 2008). Other studies have also shown that most women of 
reproductive age in the U.S. are not getting enough vitamin C or B6, in addition to folic acid 
(Cena et al., 2008 ; Yang et al., 2007).  
As previously indicated, consuming folate-rich foods or ingesting folic acid, a synthetic 
compound available through dietary supplements and through fortified foods, can increase 
folate levels. Folic acid is approximately 1.7 times more bio-available than folate, and 
therefore, has a greater efficiency in making an impact on folate levels (Neuhouser & 
Beresford, 2001).  
In the U.S, the percentage of women of childbearing age who took daily supplements 
containing folic acid increased from 28% in 1995 (prefortification) to 32% in 2003 
(postfortification) (Green-Raleigh et al., 2006), and to 40% in 2007 (US Department of Health 
and Human Services [USDHHS], 2010). One of the Healthy People 2010 objectives was to 
increase to 80% the proportion of all women of childbearing age who consume 400 μg of 
folic acid daily to reduce the risk for serious birth defects (USDHHS, 2010). Although a 
worldwide campaign contributed to progress toward this goal, approximately 60% of 
childbearing-aged women are still not consuming a daily supplement containing folic acid.  
One should note that supplementation alone is not an effective approach because one-third 
to one-half of all pregnancies in the Unites States is unplanned (Custer et al., 2008). Women 
often do not know that they are pregnant during the crucial first 4 to 8 weeks of pregnancy. 
Neural tube development occurs during this time, hence the importance of ensuring 
adequate folic acid intake. Women aged 18-24 years have the highest rate of unintended 
pregnancies in the United States (Finer & Henshaw, 2006) but remain the least aware of and 
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knowledgeable about folic acid; they are also the least likely to report consuming a 
supplement containing folic acid. Recent studies have indicated that only 39% of southern 
Australian subjects (Chan et al., 2008), and 13.5% of Canadian subjects (French et al., 2003), 
knew they should take folic acid before pregnancy. Fortifying foods with folic acid has been 
a highly effective and uniform intervention, because fortification makes folic acid accessible 
to all women of childbearing age, without requiring substantial behavioral changes. 
6.3 Reduce the number or obese or overweight women 
Overweight status and obesity have become serious global public health issues. Nearly two 
thirds of reproductive-aged women in the United States are currently overweight or obese 
(≥25 kg/m2). In the NHANES, the prevalence of obesity (BMI ≥30 kg/m2) in women aged 
20-49 years continues to be high, exceeding 30% after 1999 (Flegal et al., 2010). In the latest 
NHANES data from 2007-2008 of 877 women aged 20-39 years, the prevalence of 
overweight status (BMI ≥25 kg/m2) and obesity were 59.5% and 34.0%, respectively. 
The worldwide trend of increasing obesity may lead to increasing the incidences of NTDs. A 
population-based case-control study by Shaw et al. (1996) indicated an increased risk for 
NTD-affected pregnancies among obese women with BMIs >29 kg/m2, compared to women 
of normal pre-pregnancy BMIs (OR: 1.9, 95% CI: 1.3-2.9), when adjusted for maternal age, 
education, gravidity, use of vitamins, and use of alcohol. Rasmussen et al. (2008) conducted 
a metaanalysis of 12 published reports, including 4 cohort and 8 case-control studies 
conducted from 2000 through 2007, on the relationship between maternal obesity and the 
risk of NTDs. Unadjusted odds ratios for an NTD-affected pregnancy were 1.22 (95% CI: 
0.99-1.49), 1.70 (95% CI: 1.34-2.15), and 3.11 (95% CI: 1.75-5.46) among overweight, obese, 
and severely obese women, respectively, compared with normal-weight women. Based on 
the results of this metaanalyisis, maternal obesity was associated with a 1.7-fold increased 
risk of NTDs, and severe obesity was associated with a >3-fold increased risk. A possible 
mechanism may involve problems with glucose metabolism, because obese women are 
more likely to have pre-pregnancy diabetes mellitus, which is a well-known risk factor for 
NTDs (Becerra et al., 1990; Werler et al., 1996). However, the reasons for this association are 
not yet known. 
The risks associated with high BMI are best addressed before conception because weight 
loss during pregnancy is not recommended. Counseling to support improvements in diet 
and physical activity is a first-step intervention. All women with a BMI of 25 kg/m2 or 
greater should be offered specific strategies to improve the balance and quality of their diets, 
to decrease caloric intake, and to increase physical activity.  
7. Conclusion 
NTDs are life threatening and cause life-long disabilities. They are a worldwide problem, 
affecting an estimated 300,000 or more fetuses or infants each year. Experimental and 
epidemiological evidence has shown that periconceptional dietary supplementation with 
folic acid can result in an estimated 50-70% decrease in the prevalence of NTDs. To reduce 
more incidences of NTDs, each reproductive-aged woman must try to consume food 
fortified with folic acid and folic acid supplements and maintain adequate BMIs before 
conception. Special attention or renewed educational approaches must target reproductive-
www.intechopen.com
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aged women. Public health campaigns aimed at increasing awareness, knowledge, and 
periconceptional use of folic acid using appropriate intervention methods worldwide 
continues to be the most effective strategy.  
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